Journal of Prevention and Treatment for Stomatological Diseases ›› 2019, Vol. 27 ›› Issue (9): 545-550.doi: 10.12016/j.issn.2096-1456.2019.09.001

• Expert Forum • Previous Articles     Next Articles

Diagnosis and treatment of head and neck osteosarcoma

JI Tong()   

  1. Department of Oral and Maxillofacial Head and Neck Oncology, Shanghai Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, National Clinical Research Center of Stomatology, Shanghai 200011, China
  • Received:2019-03-31 Revised:2019-05-15 Online:2019-09-20 Published:2019-09-20
  • Contact: Tong JI E-mail:jitong70@hotmail.com

Abstract:

Osteosarcoma is the most common osteogenic malignancy of the head and neck, and its incidence in the upper mandible is predominant. Osteosarcoma of the head and neck has various causes and rich pathological subtypes. Diagnosis of osteosarcoma requires the synthesis of symptoms and imaging data and pathological characteristics (including cell characteristics, immunohistochemical characteristics and molecular markers). Surgery is the core treatment for osteosarcoma of the head and neck. Compartment resection based on the Enneking staging system has high practicability in the surgical treatment of osteosarcoma of the head and neck. Osteosarcoma can be treated by combined craniomandibular surgery to achieve complete resection of the tumor. The combination of adjuvant radiotherapy, adjuvant chemotherapy and surgery can further reduce the risk of local recurrence and distant tumor metastasis. The emergence of targeted therapy and immunotherapy provides more options for the treatment of head and neck osteosarcoma. This article reviews the diagnosis and treatment of osteosarcoma of the head and neck.

Key words: head and neck osteosarcoma, jaws, diagnosis, compartment resection, adjuvant radiotherapy, adjuvant chemotherapy, targeted therapy, prognosis

CLC Number: 

  • R78
[1] Mirabello L, Scd R, Sharon A , et al. Osteosarcoma incidence and survival rates from 1973 to 2004[J]. Cancer, 2009,115(7):1531-1543.
[2] Caron AS, Hajdu S, Strong EW . Osteogenic sarcoma of the facial and cranial bones: a review of forty-three cases[J]. Am J Surg, 1971,122(6):719-725.
[3] Chen YM, Gokavarapu S, Shen QC , et al. Chemotherapy in head and neck osteosarcoma: adjuvant chemotherapy improves overall survival[J]. Oral Oncol, 2017,73:124-131.
[4] Chen YM, Shen QC, Gokavarapu S , et al. Osteosarcoma of head and neck: a retrospective study on prognostic factors from a single institute database[J]. Oral Oncol, 2016,58:1-7.
[5] 李江, 何荣根 . 颌面部骨肉瘤61例临床病理研究[J]. 中华口腔医学杂志, 2003,38(6):444-446.
[6] 李晓, 季彤 . 颌面头颈部骨肉瘤化学治疗的研究进展[J]. 国际口腔医学杂志, 2017,44(1):83-86.
[7] Gazitt Y, Kolaparthi V, Moncada K , et al. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways[J]. Int J Oncol, 2009,34(2):551-561.
[8] Smith RB, Apostolakis LW, Karnell LH , et al. National cancer data base report on osteosarcoma of the head and neck[J]. Cancer, 2003,98(8):1670-1680.
[9] Lau CC . Molecular classification of osteosarcoma[J]. Cancer Treat Res, 2009,152:459-465.
[10] Gorlick R . Current concepts on the molecular biology of osteosarcoma[J]. Cancer Treat Res, 2009,152:467-478.
[11] 丘钜世, 朱全胜, 王连唐 . 骨肉瘤的病理类型及其病理特点[J]. 中华病理学杂志, 1997,26(5):259-261.
[12] Green D, Mohorianu I, Mcnamara I , et al. miR-16 is highly expressed in paget’s associated osteosarcoma[J]. Endocr Relat Cancer, 2017,24(5):27-31.
[13] Lie LQ, Liao, Hong HH , et al. Radiation-induced osteosarcoma of the maxilla and mandible after radiotherapy for nasopharyngeal carcinoma[J]. Chin J Cancer, 2016,35(11):625-631.
[14] 王春彦, 杨晨, 李叔强 , 等. 外伤性骨肉瘤病例报道1例及相关文献回顾[J]. 中国骨伤, 2014,27(1):69-70.
[15] 张景峰, 王跃 . WHO骨肿瘤分类第四版解读与比较[J]. 中华骨科杂志, 2015,35(9):975-979.
doi: 10.3760/cma.j.issn.0253-2352.2015.09.014
[16] Hasrayati A, Ita A, Afiati A , et al. The role of osteocalcin and alkaline phosphatase immunohistochemistry in osteosarcoma diagnosis[J]. Patholog Res Int, 2018, Doi: 10.1155/2018/6346409.
[17] Koehne AL, Sayles LC, Breese MR , et al. Abstract a35: characterization of the genomic landscape of osteosarcoma metastasis[J]. Cancer Res, 2016,76(5):35.
[18] 方三高, 马强, 杜娟 , 等. 高级别表面骨肉瘤临床病理分析并文献复习[J]. 现代肿瘤医学, 2018,26(9):1431-1436.
[19] 袁俊清, 张惠箴, 黄文涛 , 等. 骨肉瘤诊断及预后相关分子标志物的研究进展[J]. 中华病理学杂志, 2014,43(6):422-424.
[20] Inoue T, Hagiyama M, Enoki E , et al. Cell adhesion molecule 1 is a new osteoblastic cell adhesion molecule and a diagnostic marker for osteosarcoma[J]. Life Sci, 2013,92(1):91-99.
[21] Nedelcu T, Kubista B, Koller A , et al. Livin and Bcl-2 expression in high-grade osteosarcoma[J]. J Cancer Res Clin Oncol, 2008,134(2):237-244.
[22] Yang QC, Zeng BF, Shi ZM , et al. Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma[J]. J Exp Clin Cancer Res, 2006,25(4):593-599.
[23] National Comprehensive Cancer Network. NCCN guideline for bone cancer. Version 1[Z]. 2019: 20-25.
[24] 张陈平 . 口腔癌的间室外科[ C]//国际暨全国头颈肿瘤学术大会会议论文集, 2011.
[25] National Comprehensive Cancer Network. NCCN soft tissue sarcoma, Version 2[Z]. 2018: 51.
[26] Smith RB, Apostolakis LW, Karnell LH . et al. National cancer data base report on osteosarcoma of the head and neck[J]. Cancer, 2003,98(8):1670-1680.
[27] Oertel S, Blattmann C, Rieken S , et al. Radiotherapy in the treatment of primary osteosarcoma -- a single center experience[J]. Tumori, 2010,96(4):582-588.
[28] Guadagnolo BA, Zagars GK, Raymond KA , et al. Osteosarcoma of the jaw/craniofacial region outcomes after multimodality treatment[J]. Cancer, 2009,115(14):3262-3270.
[29] Zhang W, Tanaka M, Sugimoto Y , et al. Carbon-ion radiotherapy of spinal osteosarcoma with long-term follow[J]. 2016,25(1):113-117.
[30] Deutsch M, Tersak JM . Radiotherapy for symptomatic metastases to bone in children[J]. Am J Clin Oncol, 2004,27(2):128-131.
[31] 陆嘉德, 孔琳, 高晶 , 等. 质子重离子放射治疗的临床研究概况[J]. 中华放射医学与防护杂志, 2016,36(8):611-615.
[32] Kong L, Hu J, Gao J , et al. Particle radiation therapy of head and neck malignancies at the Shanghai Proton and Heavy Ion Center[J]. IJROBP, 2018,100(5):1403.
[33] Mücke T, Mitchell DA, Tannapfel A , et al. Effect of neoadjuvant treatment in the management of osteosarcomas of the head and neck[J]. J Cancer Res Clin Oncol, 2014,140(1):127-131.
[34] Sakamoto A, Iwamoto Y . Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy[J]. Rev Recent Clin Trials, 2008,3(3):228-231.
[35] Gill J, Ahluwalia MK, Geller D , et al. New targets and approaches in osteosarcoma[J]. Pharmacol Ther, 2013,137(1):89-99.
[36] Meyers PA, Schwartz CL, Krailo MD , et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children’s Oncology Group[J]. J Clin Oncol, 2008,26(4):633-638.
[37] Anninga JK, Gelderblom H, Fiocco M , et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?[J]. Eur J Cancer, 2011,47(16):2431-2445.
[38] Patel S, Delaney TF . Advanced-technology radiation therapy for bone sarcomas[J]. Cancer Control, 2008,15(1):21-37.
[39] Daw NC, Neel MD, Rao BN , et al. Frontline treatment of localized osteosarcoma without methotrexate[J]. Cancer, 2011,117(12):2770-2778.
[40] Granowski-Lecornu M, Chuang SK, Kaban LB , et al. Osteosarcoma of the jaws: factors influencing prognosis[J]. J Oral Maxillofac Surg, 2011,69(9):2368-2375.
[41] Thariat J, Julieron M, Brouchet A , et al. Osteosarcomas of the mandible: are they different from other tumor sites?[J]. Crit Rev Oncol Hematol, 2012,82(3):280-295.
[42] Thariat J, Schouman T, Brouchet A , et al. Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult--a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE[J]. Ann Oncol, 2013,24(3):824-831.
[43] Smithey BE, Pappo AS, Hill DA . C-kit expression in pediatric solid tumors -- a comparative immunohistochemical study[J]. 2002,26(4):486-492.
[44] Wilhelm SM, Carter C, Tang L , et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J]. Cancer Res, 2004,64(19):7099-7109.
[45] Grignani G, Palmerini E, Dileo P , et al. A phase Ⅱ trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study[J]. Ann Oncol, 2012,23(2):508-516.
[46] Coventon J . A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma[J]. Bone Oncol, 2017,8(8):4-7.
[47] Graaf WD, Jean-Yves B, Chawla SP , et al. Pazopanib for metastatic soft-tissue sarcoma(PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet, 2012,379(9829):1879-1886.
[48] Safwat A, Boysen A, Lucke A , et al. Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients[J]. Acta Oncol (Madr), 2014,53(10):1451-1454.
[49] Walcott BP, Nahed BV, Mohyeldin A , et al. Chordoma: current concepts, management, and future directions[J]. Lancet Oncol, 2012,13(2):e69-e76.
[50] Topalian SL, Brahmer JR, Hodi F , et al. Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: clinical activity, safety, and a potential biomarker for response[J]. J Clin Oncol, 2012,30(15):2509.
[51] Riley JL . PD-1 signaling in primary T cells[J]. Immunol Rev, 2009,229(1):114-125.
[52] Lussier DM, Johnson JL, Hingorani P , et al. Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma[J]. J Immunother Cancer, 2015,3(3):21.
[53] Shih K, Arkenau HT, Infante JR . Clinical impact of checkpoint inhibitors as novel cancer therapies[J]. Drugs, 2014,74(17):1993-2013.
[54] Koirala P, Roth M, Gill J , et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma[J]. Cancer Res, 2016,76(14):30093.
[1] WU Buling,LUO Yifei,XU Wenan,TONG Zhongchun. Vital pulp therapy of pulp inflammation of permanent teeth [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2021, 29(7): 433-441.
[2] WANG Anxun. Diagnosis and treatment of benign condylar hyperplasia [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2021, 29(6): 361-367.
[3] WANG Qianqian,DING Dandan,DING Xiang,HAN Rui,HAN Yingying,ZHOU Meiyun,XU Jincheng. Expression of Bex1 and NF-kBp65 in tongue squamous cell carcinoma and its significance [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2021, 29(6): 383-387.
[4] TAO Qian,HUANG Yun. Modern therapeutic strategies for submandibular lithiasis [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2021, 29(5): 289-295.
[5] YANG Hui,WANG Xiang,ZHANG Lei,WANG Wenmei,DUAN Ning,LI Ruowei,ZHANG Miaomiao. Clinical analysis of 19 cases of oral mucosal malignant melanoma [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2021, 29(12): 843-847.
[6] CHEN Zhen,ZHANG Wenbo,PENG Xin. Research progress on the neck management of oral squamous cell carcinoma with clinically node-positive neck [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2021, 29(11): 776-781.
[7] ZHANG Qianyu,YANG Peixin,CHEN Boshen,WANG lin,HUANG Zhiquan. Synchronous double primary malignant tumours of the tongue and lung: a case report and literature review [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(9): 586-589.
[8] LU Jie,WANG Yingju,ZHANG Lijuan,LI Fan,LI Shanshan,TAN Kaixuan,ZHANG Ying,YANG Fang. Permanent successor necrosis caused by periapical periodontitis of deciduous teeth: a case report and literature review [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(9): 590-593.
[9] TAO Qian,YANG Yaocheng. Logic and clinical significance of the new WHO classification of ameloblastoma in 2017 [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(7): 416-420.
[10] TANG Yufei,LIU Zhenzhen,ZHOU Anqi,YU Hui,ZHANG Xinyuan,WANG Bin,MA Ziyan,XIANG Lin. Risk assessment and prevention in clinical diagnosis and treatment in implant surgery associated with systemic diseases [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(7): 453-457.
[11] LI Xiaodong,MENG Jian. Application progress of recombinant human endostatin in the treatment of head and neck cancer [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(4): 267-272.
[12] WANG Yueyang,ZHANG Lili,ZHOU Weiwei,WANG Nan. Retrospective study of flexible fiber splints in the treatment of horizontal root fractures in permanent teeth [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(3): 163-168.
[13] YUAN Kaifang,CHEN Weiliang,ZHOU Bin,ZHANG Daming. Comparison of the clinical effect of a facial-submental artery island flap in reconstruction after resection of oral cavity and oropharyngeal squamous cell carcinoma [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(2): 84-87.
[14] LI Ruichun,JING Kaian,WANG Lina,MA Rui,JING Jie,MA Jian. Malformation of Wharton′s duct with multiple sialoliths: a case report and literature review [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(2): 93-96.
[15] WANG Anxun. Epigenetic and oral squamous cell carcinoma [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(10): 613-622.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] ZHU Song-song, HU Jing. The application of distraction osteogenesis in the temporomandibular joint ankylosis and secondary dentofacial deformities[J]. journal1, 2016, 24(1): 6 -10 .
[2] XU Jing. The influence of the impacted mandibular third molar extraction on the distal periodontal tissue of the mandibular second molar[J]. journal1, 2016, 24(1): 11 -14 .
[3] ZHONG Jiang-long, PAN Ji-yang, CHEN Wei-liang. The evaluation of Eagle syndrome treatment by surgery combined with antidepressant therapy[J]. journal1, 2016, 24(1): 26 -28 .
[4] CHEN Xi, SUN Qin-zhou. The study of colorimetric board of porcelain fused to metal restoration for moderate to severe dental fluorosis[J]. journal1, 2016, 24(1): 33 -36 .
[5] OUYANG Ke-xiong1, LIANG Jun, ZOU Rui, LI Zhi-qiang, BAI Zhi-bao, PIAO Zheng-guo, ZHAO Jian-Jiang.. Ion Torrent RNA-Seq detection and analysis of the long non-coding RNA in tongue squamous cell carcinoma[J]. journal1, 2016, 24(1): 15 -19 .
[6] YU Pei, XUE Jing, ZHANG Xiao-wei, ZHENG Cang-shang. The influence of the roughness of zirconia ceramic surface on microbial attachment[J]. journal1, 2016, 24(1): 20 -25 .
[7] LIU Fang. Clinical assessment of two fissure sealant techniques in children’s dental caries prevention[J]. journal1, 2016, 24(1): 44 -45 .
[8] . [J]. journal1, 2016, 24(1): 49 -52 .
[9] LU Jian-rong, BAN Hua-jie, WANG Dai-you, ZHOU Hui-hui, LONG Ru, QIN Shu-hua. Clinical observation of sternocleidomastoid muscle flaps combined with artificial biological membrane reparing the defects after parotidectomy[J]. journal1, 2016, 24(1): 29 -32 .
[10] LI Bin, HE Xiao-ning, GAO Yuan, HU Yu-ping. Clinical analysis of pain after two kinds of apical stop preparation[J]. journal1, 2016, 24(1): 40 -43 .
This work is licensed under a Creative Commons Attribution 3.0 License.